Impact of Annual Targeted Azithromycin Treatment on Infectious Trachoma and Susceptibility to Reinfectio

Phase 4

Completed

• Conditions: Trachoma; Eye - Diseases / disorders of the eye

• Registration Number: ACTRN12606000360516
• Lead Sponsor: International Trachoma Initiative

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-08-18
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 3186

Inclusion Criteria

1) all individuals in the SAFE, SA-only, and S-only communes were included in the study unless they were 6 months of age or younger; 2) For single dose oral azithromycin treatment at baseline and 12 months, school children aged 5-15 years who had active trachoma (defined as index case) and all members of their households regardless of active trachoma status were included for treatment in the SAFE and SA-only communes; 3) all other individuals in the SAFE, SA-only and S-only communes not in a household with an index case were included and were eligible for treatment with topical tetracycline if they had active trachoma.

Exclusion Criteria

All children under six months of age.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Active trachoma and Chlamydia trachomatis infection of the external eye.[Time points of the study were at baseline and at 6, 12, 18, 24 and 36 months; baseline and 12 months were the time points where index cases and their household members in the SAFE and SA-only communes received azithromycin. Thus, the follow up is 2 years beyond the second treatment with azithromycin.]

Secondary Outcome Measures

Name	Time	Method
ew infection, continuing infection and reinfection.[At 6, 12, 18, 24, and 36 months.]